LAIV Inducing Cross Protection

LAIV 诱导交叉保护

• 批准号: 8951382
• 负责人: SANG-MOO KANG
• 金额: $ 18.76万
• 依托单位: GEORGIA STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-05-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8951382
• 关键词: 2 year old; Adult; Animal Model; Antibodies; Antibody Response; Attenuated; Attenuated Vaccines; Child; Development; Epidemic; Epitopes; Ferrets; Figs - dietary; Genes; Goals; Head; Hemagglutinin; Human; Immune response; Immunity; Inactivated Vaccines; Influenza; Influenza A Virus, H1N1 Subtype; Influenza A Virus, H5N1 Subtype; Influenza A virus; Influenza vaccination; Licensing; Life; M2 protein; Mus; Mutation; Phenotype; Polymerase; Proteins; Public Health; Recombinants; Safety; Site; Supplementation; Tandem Repeat Sequences; Testing; Vaccinated; Vaccines; Variant; Vertebral column; Virus; attenuation; base; immunogenic; immunogenicity; improved; influenza virus vaccine; influenzavirus; mutant; novel; novel strategies; pandemic disease; protective efficacy; public health relevance; recombinant virus; vaccine trial; vector vaccine

 DESCRIPTION (provided by applicant): Live attenuated influenza vaccine (LAIV) is a safe and effective platform for human use, and shown to have higher efficacy in children than inactivated vaccine. Nonetheless, current influenza vaccines including LAIV do not provide cross-protection against antigenically distinct epidemic strains or the unanticipated emergence of new pandemic strains. It is of a high priority to improve the breadth of cross protective efficacy of strain-specific vaccines based on hemagglutinin (HA) immunity. Our preliminary studies demonstrated that immune responses to highly conserved influenza M2 protein (M2e) provided a broader range of cross-protection (H1, H3, and H5 subtypes). In addition, we recently generated novel influenza mutants that express a chimeric conserved M2e-HA, which showed attenuated phenotypes as well as provided significantly broad and enhanced cross-protection. These findings strongly suggest that it should be possible to produce highly cross protective and safe LAIV. Thus, it is highly expected that incorporating conserved-protective M2e into HA will overcome the strain-specific protection of HA as well as poor immunogenicity of M2. The central hypothesis is that recombinant LAIV containing M2e-HA will be safer and more effective in inducing a broader range of cross-protection. The first goal (aim 1) is to generate recombinant LAIV containing M2e-HA and to determine the safety and cross-protective efficacy of recombinant LAIV. The aim 2 will test recombinant LAIV-M2e vaccines in ferrets, which is a more relevant animal model for testing influenza vaccines.

 产品描述（申请方提供）：流感减毒活疫苗（LAIV）是一种安全有效的人用平台，在儿童中的有效性高于灭活疫苗。尽管如此，目前的流感疫苗，包括LAIV不提供针对抗原性不同的流行毒株或新的大流行毒株的意外出现的交叉保护。提高基于血凝素（HA）免疫的毒株特异性疫苗的交叉保护效力的广度是一个高度优先事项。我们的初步研究表明，对高度保守的流感M2蛋白（M2 e）的免疫应答提供了更广泛的交叉保护（H1，H3和H5亚型）。此外，我们最近产生了表达嵌合保守M2 e-HA的新型流感突变体，其表现出减弱的表型，并提供了显著广泛和增强的交叉保护。这些发现有力地表明，应该有可能产生高度交叉保护和安全的LAIV。因此，高度期望将保守保护性M2 e并入HA中将克服HA的菌株特异性保护以及M2的不良免疫原性。中心假设是含有M2 e-HA的重组LAIV在诱导更广泛的交叉保护方面将更安全和更有效。第一个目标（目的1）是产生含有M2 e-HA的重组LAIV，并确定重组LAIV的安全性和交叉保护效力。目的2将在雪貂中测试重组LAIV-M2 e疫苗，雪貂是测试流感疫苗的更相关动物模型。